Cold chain, reconstitution and room temperature: what the stability data actually covers
Peptides travel and sit at room temperature, and suppliers print storage statements anyway. Here is what the published stability literature does and does not say about a lyophilised vial — the four variables it measures, the four degradation pathways it finds, and why no published study covers the material sold on this bench.
1 October 2026
Send me the checklist
One email when a new hub goes up. Research use only; nothing else, and one click to leave.
Nothing on this bench travels in a cold chain, nothing sits in a fridge, and every product page carries a storage line anyway. That is not a contradiction — a freeze-dried vial in sealed packaging is the stable presentation, and the formulation literature is largely about protecting it. It does mean the storage statement on a page is a handling instruction, and a handling instruction is not a measurement.
This page is the evidence side of that. The practical mechanics are on storage and handling. What follows is what the stability literature actually establishes, and where it stops.
What the studies measure
The published work on peptide stability clusters around four variables: temperature, relative humidity, water content and concentration. Each of the studies below measured one or more of them deliberately, on a characterised formulation, over weeks to months.
Excursion temperature. One study took a lyophilised model peptide hormone and stored samples at −20 °C, 4 °C, 25 °C and 25 °C/60%RH, then assayed at weeks 0, 1, 4 and 8. Content fell 20–27% by week 8. At 25 °C/60%RH the particle size in reconstituted material grew from about 390 nm at day 0 to over 2 µm as early as week 1, and reconstitution time went from about 20 s to about 67 s at week 8. That is a measurable, time-dependent, formulation-specific result — and it is not a statement about any other peptide.
Post-reconstitution concentration. For teriparatide, the lyophilised solid was stable for months on storage, and then the reconstituted solution varied considerably depending on peptide concentration and storage temperature, with precipitation within two to four weeks in some samples. Equivalent samples that had not been lyophilised showed no precipitation over twelve weeks. The freeze-drying step, in that case, made the reconstituted material less stable, not more — which is a genuinely counter-intuitive result and the reason reconstitution guidance is written as carefully as it is.
Moisture and the air-solid interface. Lyophilised insulin stored under controlled humidity showed small structural changes already at 11% relative humidity, with the structural consequences worsening at higher humidity. In a separate study of lyophilised human growth hormone, the fraction of the protein sitting at the air-solid interface — not the bulk water content, which was independent of the freeze-drying cycle used — was what tracked aggregation, oxidation and deamidation over 16 weeks. In a third, peptide-excipient adducts were detected in the lyophilised solid, and the conversion to peptide-water adducts in that solid correlated poorly with bulk moisture content: the local water content near the peptide was not the measured average.
Formulation itself. Which bulking agent the manufacturer chose changed the outcome — in one antibody formulation, partially amorphous glycine increased stability where mannitol provided little. That is the general lesson: a stability result belongs to the formulation it was measured on, and it does not transfer to a different excipient set, a different vial or a different manufacturer.
Why nobody prints a stability figure for research material
A stability claim has a shape, and the shape is specified. ICH Q1A(R2) is the guideline that defines it: a protocol with defined storage conditions, defined time points, a batch or batches, and an assay shown to be stability-indicating — meaning one that would register a degraded sample as degraded rather than as a slightly shifted peak.
The paper that characterised two years of ambient stability for PTH(1-34) is a good illustration of what that actually involves: a designed study, stabilisers chosen for the purpose, and packaging engineering down to nitrogen purging and desiccant. The packaging was not a detail. It was doing part of the work.
Now apply that to a vial of research material bought from a supplier. Nobody characterised the starting material, so there is no defined substance to follow. Nobody set a protocol, so there are no time points and no acceptance criteria. Nobody ran a stability-indicating assay, so there is no evidence that any number attached to it would have registered degradation at all.
There is no stability study for material sold this way, and there cannot be, because producing one would require the characterisation that never happened. That is the honest position, and it is why this site prints a supplier’s storage instruction as an instruction and does not print a number beside it.
The four degradation pathways
Aggregation, oxidation, deamidation and isomerisation come up repeatedly across this literature. The practical consequences differ by presentation: aggregation is what turns a clear reconstituted solution cloudy and lengthens reconstitution time; oxidation is what the stabiliser and the packaging exist to slow; deamidation and isomerisation are the two that a method not validated as stability-indicating is most likely to miss, because they produce a species that still absorbs and still elutes.
The one piece of guidance that generalises across peptides is about the lab work rather than the vial. A ten-month longitudinal study of peptides stored in acid concluded that the correct handling is −80 °C in separate aliquots, and that storage in the fridge is not the substitute people assume it is. That is a finding about proteomics sample preparation, and it is stated here because it is the clearest available example of the general shape: an answer that only exists because somebody ran a study long enough to find it.
What we do not publish
We publish the supplier’s own text and storage statements verbatim, and we add no claim of our own. We do not publish a stability figure, a shelf life or a reconstitution window for any vial, because no supplier on this bench publishes one and we will not invent it. We do not repack, we do not relabel, and we cannot promise that a vial will retain anything to a stated percentage at a stated date. Where a supplier does publish batch paperwork, send your order number and we request it for the batch that actually shipped.
⚠ Everything sold here is for in-vitro laboratory research only. Not for human or veterinary use.
What each kind of storage claim rests on
| What | What the claim is | What would have to be measured to support it | What the literature on this subject actually covers | What it means for you |
|---|---|---|---|---|
| "Store refrigerated, 2–8 °C" | That activity or content is retained across the stated temperature for the stated period | A designed stability protocol with time points, a stability-indicating assay, and containers matching the ones that ship | Not the shelf. Stability studies in this field are run on characterised pharmaceutical formulations with named excipients, not on material bought as research reagent | The refrigeration instruction is the one a supplier copies most often and supports least often. Nobody has run this study on this material. |
| "Store at room temperature, protected from light" | That the presentation tolerates ambient excursion over the shelf period without measurable change | Excursion studies at controlled temperature and relative humidity, with the assay shown to be stability-indicating | Formulation-specific. One study stored a lyophilised peptide at −20 °C, 4 °C, 25 °C and 25 °C/60%RH for up to 8 weeks and found a 20–27% fall in content by week 8 at the warm end | The literature supports freeze-dried solid presentations as the stable form. That is a real finding about a class of formulations, and it is not a finding about your vial. |
| "Reconstitute and use within X hours or days" | That the reconstituted solution retains content and does not aggregate over that window | Post-reconstitution stability at the working concentration, in the actual diluent, at the actual storage temperature | Concentration-dependent and temperature-dependent in a way that is documented — one formulation showed precipitation within two to four weeks in some samples and none in twelve weeks in comparable non-lyophilised material | Once water is added the questions change, and the guidance changes with them. This is where a shelf-life claim actually stops being about the solid. |
| "Store the vial as supplied, do not refrigerate after opening" | Nothing measurable; this is handling guidance derived from someone else's data | Whatever study the instruction was taken from, and whether it was run on this formulation | The instruction is a reasonable default and is not a data point. Where nobody publishes the underlying study, we say so rather than paraphrasing the instruction as evidence | Every storage line on a product page here is somebody's handling advice. We print it as advice, and this page is where the line between advice and evidence is drawn. |
Questions this page answers.
Does a peptide vial need a cold chain in transit?
Nothing on this bench travels refrigerated and nothing needs to. Freeze-dried peptide in its sealed vial is the stable presentation, and the literature reflects that — the formulation studies are about protecting a lyophilised solid, not about rescuing a liquid one. The moments that matter are after reconstitution, when the material is a solution again, and there the storage temperature and the concentration are the variables that move the result.
What actually degrades a lyophilised peptide?
Four pathways come out of the literature repeatedly: aggregation, oxidation, deamidation and isomerisation. One study that characterised solid-state stability found that the amount of human growth hormone sitting at the air-solid interface, not the bulk water content, tracked the degradation rate — which is why two samples with the same measured water content can behave differently.
Is there stability data for the vials sold on this site?
No. That is stated plainly because the alternative is inventing one. The published studies in this field are conducted on characterised pharmaceutical formulations, inside a pharmaceutical quality system, on a specific peptide in a specific formulation with named excipients. There is no stability study for research material bought by the vial from a supplier, and there cannot be, because nobody characterised it. We do not publish stability figures and we do not paraphrase a supplier's handling instruction as though it were one.
What does this shop publish, and what does it not?
We publish the supplier's own text and storage statements verbatim on each vial's page and add no claim of our own. We do not publish a stability figure, a shelf life or a reconstitution window for any vial, and we do not present a supplier's handling instruction as a measured result. Send your order number and we request the batch paperwork from the supplier for the batch that actually shipped.
Where this comes from.
- Srinivasan C, Siddiqui A, Korang-Yeboah M, Khan MA. Stability characterization and appearance of particulates in a lyophilized formulation of a model peptide hormone — human secretin. Int J Pharm 2015;481(1-2):104-113. (PMID 25636302) — samples stored at −20 °C, 4 °C, 25 °C and 25 °C/60%RH, analysed at 0, 1, 4 and 8 weeks; secretin content fell 20–27% by week 8; at 25 °C/60%RH particle size grew from ~390 nm at day 0 to over 2 µm by week 1 and reconstitution time from ~20 s to ~67 s at week 8.
- Merutka G, Murphy BM, Payne RW, et al. Stability of lyophilized teriparatide, PTH(1-34), after reconstitution. Eur J Pharm Biopharm 2016;99:84-93. (PMID 26620825) — lyophilised formulations stable for months in the solid state; after reconstitution, precipitation within two to four weeks in some samples depending on concentration and temperature; comparable non-lyophilised samples showed no precipitation over twelve weeks.
- Planyavsky M, Huber ML, Staller NA, Müller AC, Bennett KL. A longitudinal proteomic assessment of peptide degradation and loss under acidic storage conditions. Anal Biochem 2015;473:11-13. (PMID 25479603) — a 10-month study at −20 °C and −80 °C concluding that aliquots at −80 °C are the correct handling for peptides in acid.
- Chen Y, Topp EM. Quantitative Analysis of Peptide-Matrix Interactions in Lyophilized Solids Using Photolytic Labeling. Mol Pharm 2018;15(7):2797-2806. (PMID 29792715) — peptide-excipient adducts formed in the lyophilised solid; conversion to peptide-water adducts in the solid correlated poorly with bulk moisture content, so local water activity governs and the bulk average does not.
- Meyer JD, Nayar R, Manning MC. Impact of bulking agents on the stability of a lyophilized monoclonal antibody. Eur J Pharm Sci 2009;38(1):29-38. (PMID 19467324) — the excipient a manufacturer chose changes the stability outcome, which is why a result does not transfer to another formulation.
- Angkawinitwong U, Sharma G, Khaw PT, Brocchini S, Williams GR. Solid-state protein formulations. Ther Deliv 2015;6(1):59-82. (PMID 25565441) — why solid formulations are required at all, and the physical instabilities they exist to control.
- Flores-Fernández GM, Solá RJ, Griebenow K. The relation between moisture-induced aggregation and structural changes in lyophilized insulin. J Pharm Pharmacol 2009;61(11):1555-61. (PMID 19903382) — small structural changes in lyophilized insulin already at 11% relative humidity, becoming more pronounced at higher humidity.
- Xu Y, et al. Protein quantity on the air-solid interface determines degradation rates of human growth hormone in lyophilized samples. J Pharm Sci 2014;103(5):1356-1366. (PMID 24623139) — degradation tracked the fraction of protein at the surface of the cake rather than bulk water content; aggregation, oxidation and deamidation after 16 weeks at 323 K.
- Ameri M, et al. Demonstrated solid-state stability of parathyroid hormone PTH(1-34) coated on a novel transdermal microprojection delivery system. Pharm Res 2009;26(11):2454-2463. (PMID 20183917) — what it takes to claim two years at ambient temperature: a designed study, stabilisers, and nitrogen-purged foil with desiccant.
- ICH Q1A(R2) Stability Testing of New Drug Substances and Products — the guideline that defines what a stability claim is allowed to mean, and what a protocol has to contain.
